通过运用计算机辅助药物设计、化学生物学、药物化学等多学科交叉手段，基于针对蛋白伴侣系统及肿瘤免疫系统开展创新药物研发工作。

1、科研项目
（1）国家自然科学基金委员会，面上项目，82073766，基于STING的“开放-闭合”动态激活构象发现、设计新型STING激动剂及其在 肿瘤免疫治疗中的应用探索。2021-01 至 2024-12，56万元，在研，主持
（2）国家自然科学基金委员会，面上项目，81872737，基于诱导Phe199位移变化策略选择性抑制热休克蛋白内质网亚型Grp94蛋白的药物发现及其应用探索， 2019-01 至 2022-12，56万元，在研，主持
（3）中国药科大学中央业务高校原创探索项目，2632022YC05，cGAS-STING 信号传导的新机制发现与分子设计研究，2022-01 至 2024-12，40万元，在研，主持
（4）江苏省自然科学基金，面上项目，基于STING动态激活构象设计、发现新型STING激动剂及其在肿瘤免疫治疗中的应用探索。2020-07 至 2023-06，10万元，在研，主持
（5）国家自然科学基金青年基金项目，81502990，热休克蛋白Hsp90 C-端调控剂的发现、设计及其化学生物学研究，2016.01至2018.12，17.9万，结题，主持。
（6）江苏省基础研究计划（自然科学基金）青年基金项目，BK20150691，基于化学和生物信息学技术的Hsp90 C-端调控剂的发现、优化和作用模式研究，2015.7-2018.6，20万，结题，主持。

[1]. Qiangsheng Zhu, Nannan Chen, Xinjian Tian, Yeling Zhou, QiDong You*, and Xiaoli Xu* Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective. J. Med. Chem. 2022, 65, 12, 8065–8090.
[2]. Li Li, Nannan Chen, Dandan Xia, Shicheng Xu, Wei Dai, Yuanyuan Tong, Lei Wang, Zhengyu Jiang*, Qidong You*, Xiaoli Xu*.  Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification. Cell Chemical Biology. 2021.28（10), 1446-1459.e6.
[3]. Shicheng Xu, Anping Guo, Nan-nan Chen, Wei Dai, Huan-aoyu Yang, Wenqin Xie, Mengjie Wang, Qi-Dong You*, Xiao-Li Xu*. Design and synthesis of Grp94 selective inhibitors based on Phe199 induced fit mechanism and their anti-inflammatory effects. Eur. J. Med. Chem. 2021.223, 113604.
[4] LeiWang, JingshengJiang, LixiaoZhang, QiuyueZhang, JianruiZhou,Li Li, Xiao-li Xu,* Qidong You*.Discovery and Optimization of Small Molecules Targeting theProtein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer J. Med. Chem. 2020 63 (3), 1281-1297.
[5]. Han Zhang，Qi-Dong You*，Xiao-Li Xu* Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective J. Med. Chem.2020, 63 (8):3785-3816
[6]. Li Li, Lei Wang, Qi-Dong You,* and Xiao-Li Xu* Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. J. Med. Chem. 2020, 63, 5, 1798-1822. IF: 6.023.
[7]. Fen Jiang, An-ping Guo, Jia-chen Xu, Qi-Dong You,*Xiao-Li Xu* Discovery of a Potent Grp94 Selective Inhibitor with Anti- Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis. J. Med. Chem. 2018, 61, 9513−9533.
[8]. Fen Jiang, Hui-Jie Wang, Yu-Hui Jin, Qiong Zhang, Zhi-Hui Wang, Jian-Min Jia,Fang Liu, Lei Wang,Qi-Chao Bao, Dong-Dong Li, Qi-Dong You,*and Xiao-Li Xu*.Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90. J. Med. Chem. 2016, 59, 10498-10519.
[9]. Wang, L.1; Xu, X.1; Jiang, Z.*; You, Q.*, Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery. 2020. Acta Pharm Sin B. 2020. 10(10):1904-1925.
[10]. Xiao-li Xu, Ying-rui Yang, Xiao-fei Mo, Jin-lian Wei, Xiao-jin Zhang, You, Q. D* Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1a pathway. Eur. J. Med. Chem., 2017, 137, 45-62.